Court Revives Zicam Complaint, But Says Disclosure Remains Case-by-Case
This article was originally published in The Tan Sheet
Executive Summary
An appellate court decision supporting a complaint against Matrixx Initiatives related to its over-the-counter cold remedy Zicam shows that determining what information firms must disclose is a "delicate," case-by-case process
You may also be interested in...
Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."
Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."
Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."